compound semaglutide injections FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products Troubling Findings in Study of

Clinical Efficacy and Evidence Considerations Wegovy's efficacy in weight loss and metabolic improvement is well-documented through randomized controlled trials (STEP program), demonstrating approximately 1522% body weight reduction at 2.4 mg dosing over 68 weeks

(2023, April 28)

If more than 4 days have passed, skip the missed dose and resume your regular schedule

See the dosing protocol for the specific weekly schedule

Patients should be counseled never to administer extra doses to make up for missed doses, as this could increase the risk of adverse effects without providing additional therapeutic benefit

As one of the fastest growing classes of medications, GLP-1 weight-loss drugs were originally brought on the market to treat diabetes